Principal Investigators

Principal Investigators

Dr. MICHAEL R. HAYDEN

Michael Hayden

"My research has concentrated on how changes in specific genes result in specific diseases, leading to new approaches to treatment."

Dr. ELIZABETH CONIBEAR

Elizabeth Conibear

"In my research I try to understand how cells are able to transport, store and recycle different molecules particularly lipids like cholesterol. In the lab we work with yeast cells before studying the human equivalents in tissue culture cells."

Dr. DANIEL GOLDOWITZ

Daniel Goldowitz

"Our laboratory uses mouse mutants and experimental embryology and reference populations to study how single genes, or ensembles of genes, participate to support the normal development and function of the central nervous system."

Dr. CLARA VAN KARNEBEEK

Clara van Karnebeek

"The goal of my research program is to harness '-omics' technologies to identify and treat genetic defects that lead to intellectual disability, and to develop tools to assist physicians with the diagnosis and treatment of these conditions before permanent brain damage occurs."

Dr. MICHAEL S. KOBOR

Michael S. Kobor

"The focus of our laboratory is the molecular biology of chromatin structures and their role in chromosome biology and genome function in health and disease."

Dr. BLAIR R. LEAVITT

Blair Leavitt

"My laboratory is dedicated to developing a highly quantitative approach to screening novel therapeutics in order to accelerate the progress of clinical treatments of neuro-degenerative disorders."

Dr. SARA MOSTAFAVI

Sara Mostafavi

"Research at the Mostafavi lab focuses on developing computational and statistical approaches for integrating and interpreting diverse types of genomics data, with the ultimate goal of disentangling meaningful molecular associations for common and complex pathologies, such as neurodegenerative and psychiatric disorders."

Dr. ELIZABETH M. SIMPSON

Elizabeth Simpson

"The overall goal of my research is to develop gene-based therapies for diseases of the brain and eye. My approach is to use rAAV (recombinant adeno-associated virus) to deliver therapies to treat mouse models of human disease. Currently, we are mining the human genome for cell-type-specific promoters to use in viruses, and developing gene augmentation and genome editing (CRISPR/cas9) therapies focused on curing the congenital blindness aniridia."

Dr. STEFAN TAUBERT

Stefan Taubert

"We use the nematode Caenorhabditis elegans and mammalian cell culture systems to dissect transcriptional regulatory networks that affect lipid metabolism, responses to nutritional stresses—such as fasting, toxins, heavy metals, oxidation, and pathogens—and developmental processes."

Dr. WYETH W. WASSERMAN

Wyeth Wasserman

"Our research explores the regulatory controls governing gene expression. As a bioinformatics computational biology group, we develop statistically-driven alogorithms to find and characterize regulatory controls regions in genome sequences. We aim to discover mutations in regulatory sequences contributing to genetic disease."